Benoîte Mery (Benoite Mery)

Years Active: 2023-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Benoîte Mery, Christine Ménétrier-Caux, Laure Montané, Pierre-Etienne Heudel, Isabelle Ray-Coquard, Thomas Bachelot, Olfa Derbel, Paule Augereau, Isabelle Treilleux, Justine Berthet, Axelle Nkodia, Christine Bardin-Dit-Courageot, Valery Attignon, Anthony Ferrari, Gwenaele Garin, David Perol, Christophe Caux, Bertrand Dubois, Olivier Trédan
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. Breast cancer (Dove Medical Press) 15 (2023)
Benoîte Mery, Christine Ménétrier-Caux, Laure Montané, Pierre-Etienne Heudel, Isabelle Ray-Coquard, Thomas Bachelot, Olfa Derbel, Paule Augereau, Isabelle Treilleux, Justine Berthet, Axelle Nkodia, Christine Bardin-Dit-Courageot, Valery Attignon, Anthony Ferrari, Gwenaele Garin, David Perol, Christophe Caux, Bertrand Dubois, Olivier Trédan
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. Breast cancer (Dove Medical Press) 15 (2023)
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoîte Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα + breast cancer. EMBO molecular medicine (2023)

Benoîte Mery.css-eqlu8i{font-size:small;padding-left:4px;} (Benoite Mery)